Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANVS
STRONG SELLAnnovis Bio, Inc. · Healthcare · United States · $71M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Annovis Bio, Inc. is a clinical-stage drug platform company developing novel therapies to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's competitive moat is its lead compound, buntanetap, which targets multiple neurotoxic proteins simultaneously to restore axonal transport. It operates as a specialized biotechnology player focused on disease-modifying neuroprotective treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.59 | -1.54 | -0.67 | -1.40 | — | -1.71 | -1.69 | -0.89 | — |
| Shares | 42.5M | 42.5M | 42.5M | 27.2M | -36.1% | — | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 28.3M | -7.8M | 9.3M | 16.9M | -15.9% | — | — | — | — |
| Op CF | -17.3M | -40.0M | -21.9M | -25.6M | — | -26.5M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | 4.6K | 17.3M | 26.7M | 34.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANVS | Annovis Bio, Inc.(you) | $71M | 8 | STRONG SELL |
| IBIO | iBio, Inc. | $71M | 8 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $66M | 8 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $75M | 7 | STRONG SELL |
| HYFT | MindWalk Holdings Corp. | $64M | 8 | STRONG SELL |
| TELO | Telomir Pharmaceuticals, Inc. | $79M | 9 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| KALA | KALA BIO, Inc. | $63M | 9 | STRONG SELL |
| HRTX | Heron Therapeutics, Inc. | $86M | 8 | STRONG SELL |
| MAIA | MAIA Biotechnology, Inc. | $75M | 12 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.6%